Additionally, apoptosis assay and cell cycle analysis to examine whether tamoxifen upon SLC1A5 knockdown induces cell death or cell cycle arrest are potential studies to be performed The predictive value of SLC1A5 on the benefit of endocrine therapy will also require further investigation in clinical trials of primary breast cancer treatment. This evidence concerns the gene SLC1A5 and breast carcinoma.